Gupta A, Gonzalez-Rojas Y, Juarez E, et al. - Findings from the ongoing, multicenter, double-blind, phase 3 trial of sotrovimab in nonhospitalized patients with symptomatic Covid-19 (randomized ≤ 5 days after the onset of symptoms) and at least one risk factor for disease progression, were assessed for the rate of hospitalization (for > 24 hours) for any cause or death in correlation with receiving treatment with sotrovimab.

• The prespecified interim analysis included the intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group); disease progression leading to hospitalization or death was recorded for 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group.

• Assessment of safety was done in 868 patients (430 in the sotrovimab group and 438 in the placebo group).

• Overall findings revealed correlation of receiving sotrovimab with reduced risk of disease progression.

• There were no safety signals identified.